US FDA publishes 200 rejection letters in transparency push

July 10 (Reuters) - The U.S. Food and Drug Administration on Thursday published more than 200 of its so-called complete response letters to drugmakers, a significant move to increase transparency of the agency's work.

The published letters were issued in response to marketing applications of certain drugs or therapies submitted to the FDA between 2020 and 2024.